| Name | Title | Contact Details |
|---|
The RNS® System is an award-winning technology developed and manufactured in Silicon Valley that has been recognized for its innovation. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System is the world`s first and only medical device that can monitor and respond to brain activity. NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. The company`s initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.
Saint Mary Regional Medical Center is a Apple Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
PathWell Health is a Medicare certified home healthcare agency that offers skilled nursing and therapy services to help patients maintain independence and quality of life in the comfort of their own homes.
At Gynesonics our mission is to design and develop new and advanced technologies for improving women`s health. We are focused on providing an incision-free option to women and the physicians who care for them, in treating symptomatic uterine fibroids. We are initiating a pivotal IDE trial in the United States to verify the safety and efficacy of the Sonata system, in preserving the uterus while treating those fibroids associated with abnormal uterine bleeding that are difficult to treat with existing technology and surgical techniques. We are committed to providing women with a safe and effective incision-free alternative to the invasive surgical techniques of hysterectomy or myomectomy for their severe menstrual symptoms associated with fibroids.